Evidence map›Paper›PMID 18566018›Full record

ArticleCarcinogenesis2008

Double-strand breaks repair in lymphoblastoid cell lines from sisters discordant for breast cancer from the New York site of the BCFR.

Nicola Machella, Mary Beth Terry, Jennifer Zipprich, Irina Gurvich, Yuyan Liao, Ruby T Senie, David O Kennedy, Regina M Santella

Abstract read
In one paragraph

Article in Carcinogenesis, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
  7. Review
  8. Article
  9. Review
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Nicola MachellaDepartment of Environmental Health Sciences, Epidemiology, Mailman School of Public Health, Columbia University, New York, NY 10032, USA.
Mary Beth Terry
Jennifer Zipprich
Irina Gurvich
Yuyan Liao
Ruby T Senie
David O Kennedy
Regina M Santella

Funding

Tumor Biology and Microenvironment ProgramP30CA013696 · NCI · COLUMBIA UNIV NEW YORK MORNINGSIDE · PI Parisa Tehranifar · 1985 to 2026
$115.3M
True Metal fac coreP30ES009089 · NIEHS · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI MATTHEW S PERZANOWSKI · 1998 to 2026
$44.7M
Northern California Cooperative Family Registry for Breast CancerU01CA069417 · NCI · NORTHERN CALIFORNIA CANCER CENTER · PI JOHN, ESTHER M. · 1995 to 2010
$22.4M
METROPOLITAN NEW YORK REGISTRY OF BREAST CANCER FAMILIESU01CA069398 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI TERRY, MARY BETH · 1995 to 2010
$10.5M
ONTARIO REGISTRY FOR STUDIES OF FAMILIAL BREAST CANCERU01CA069467 · NCI · CANCER CARE ONTARIO · PI ANDRULIS, IRENE L. · 1995 to 2010
$10.4M
Philadelphia Breast Cancer Family RegistryU01CA069631 · NCI · FOX CHASE CANCER CENTER · PI DALY, MARY BERYL · 1995 to 2010
$7.4M
THE AUSTRALIAN BREAST CANCER FAMILY REGISTRYU01CA069638 · NCI · UNIVERSITY OF MELBOURNE · PI HOPPER, JOHN L · 1995 to 2010
$6.6M
Utah Breast Cancer Family RegistryU01CA069446 · NCI · UNIVERSITY OF UTAH · PI BUYS, SAUNDRA S · 1995 to 2010
$4.6M
Redox Regulation of Metastasis by Sod2K22CA095011 · NCI · ALBANY MEDICAL COLLEGE · PI MELENDEZ, JUAN ANDRES · 2002 to 2004
$446k
NCI NIH HHS P30 CA013696NCI NIH HHS P30 CA13696NCI NIH HHS RFA # CA-95-011NCI NIH HHS U01 CA069398NCI NIH HHS U01 CA069417NCI NIH HHS U01 CA069446NCI NIH HHS U01 CA069467NCI NIH HHS U01 CA069631NCI NIH HHS U01 CA069638NCI NIH HHS U01 CA69398NCI NIH HHS U01 CA69417NCI NIH HHS U01 CA69446NCI NIH HHS U01 CA69467NCI NIH HHS U01 CA69631NCI NIH HHS U01 CA69638NIEHS NIH HHS P30 ES009089
6 · The paper itself

Abstract

Unrepaired DNA double-strand breaks (DSBs) may have serious consequences for cells by inducing chromosomal aberrations, thereby increasing genetic instability and cancer risk. One's capacity to repair DSB is therefore an important factor to consider when estimating cancer risk. We assessed DNA end-joining (EJ) capacity in cell lines derived from sisters discordant for breast cancer to determine if individual differences in DSB repair are a significant risk factor. We used an in vitro phenotypic assay on nuclear extracts from lymphoblasts of 179 subjects including 86 cases and 93 controls. EJ activity was functionally estimated as the ability of extracts to join together monomers of the plasmid pUC18 linearized either with sticky (EcoRI) or blunt ends (HincII). Mean percentage of EJ capacity was slightly lower in cases than controls, both for EcoRI (cases 27.9 +/- 11.1; controls 29.6 +/- 10.7, P = 0.28) and HincII substrates (cases 28.8 +/- 12.2; controls 30.6 +/- 13.0, P = 0.36); however, no significant differences were observed. Categorizing EJ capacity into tertiles and using the highest activity as the referent, we observed elevated associations for each tertile of decreased repair [Odds ratio (OR) = 2.20, 95% confidence interval (CI) = 0.77-6.22 and OR = 4.22, 95% CI thinsp;= 1.22-14.0, P = 0.02], respectively, for EcoRI. Results were not statistically significant for HincII (OR = 1.37, 95% CI = 0.51-3.70 and OR = 2.32, 95% CI = 0.57-9.38, P = 0.24). These data suggest that individual differences in EJ capacity may represent a risk factor predisposing women to breast cancer.

Indexed as

DNA Breaks, Double-StrandedDNA RepairBreast NeoplasmsCell Line, TumorCell Transformation, NeoplasticDNA, NeoplasmFemaleGenetic Predisposition to DiseaseHumansLymphocytesMiddle AgedSiblingsDNA, Neoplasm

Identifiers

PMID18566018
PMCPMC2899852

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.